Lokavant Releases Sophisticated, AI-Powered Clinical Trial Forecasting Solution to Dispel Uncertainty in Study Feasibility

Yahoo

23-04-2025

Spectrum v15 reduces 5 weeks of manual work to 5 minutes, provides study sponsors and CROs a fast way to navigate the path to successful enrollment
NEW YORK, April 23, 2025--(BUSINESS WIRE)--Lokavant, the clinical trial intelligence company, today released Spectrum v15, the most sophisticated, AI-powered clinical trial forecasting solution. Spectrum uses machine learning, generative AI, and causal AI models powered by its historical data set from 500,000 trials to dispel uncertainty about the probability of achieving key last-patient-in milestones. Teams can dynamically model study feasibility based on different site and country combinations and other inputs prior to study start and continuously for iterative analyses and mid-study course correction. Manual work to set up forecasting comparators that required at least five weeks now takes five minutes with Spectrum, driving forecasts with 80+% confidence.
Recent industry volatility, compounded by increased trial complexity, timelines, and costs, is not sustainable. To gain control, study teams need a way to predict key success factors and understand how changes, such as different site activations, could impact timelines and budgets. Traditionally, study teams spend weeks painstakingly analyzing study feasibility data, manually searching for past trials that simulate their own. The results are often inaccurate and do not take into consideration unique interdependencies between data and changes that happen during a clinical trial, such as protocol amendments or participant discontinuation. Spectrum accounts for these fluctuating dynamics and constantly re-adjusts its forecasts in kind.
"In an industry grappling with increasing complexity and volatility, we must move beyond static feasibility assumptions toward dynamic, data-driven adaptability. Solutions like Spectrum exemplify the next generation of intelligent trial design," said Jonathan Crowther, Pfizer Head of Predictive Analytics. "This isn't just operational efficiency, it's strategic foresight."
Crowther continued, "The ability to continuously model feasibility and scenario-plan with real-time responsiveness enables R&D organizations to make confident, early-stage decisions that de-risk timelines, optimize budget allocations, and accelerate portfolio value realization. It brings us closer to a future where clinical development is not reactive, but anticipatory and resilient."
Spectrum now delivers the following key advantages:
Granular forecasting at all levels – In pre-study and mid-study analysis, study teams can enter site, country, region, and study-level forecasting inputs across enrollment, discontinuation, and screen failure, while accounting for non-enrolling sites. Get detailed projections for each site, country, region – and at the study level.
Adaptive trial design forecasting – Configure forecasts based on adaptive trial designs with the flexibility to define multiple enrollment-driven interim analyses and other study pauses.
Set and achieve screening goals – In pre-study and mid-study analysis, model participant screening volumes at site, country, region, or study level required to achieve study-level enrollment goals based on screen failure, discontinuation, and enrollment rates at each of these geographic levels.
Real-time continuous (re)forecasting – With real-time integration of live study data, study teams can continuously track ongoing study startup and enrollment and generate alternative study scenarios to ensure enrollment success.
Spectrum is powered by Lokavant's Clinical Intelligence Platform, built with deep, historical trial data with integrated timelines for country approval, site startup, and enrollment rates, derived from more than 500,000 historical studies. The platform enables sponsors and CROs to forecast clinical trial enrollment success and accurately see real-time trial performance to optimize decision-making in minutes. The solution is already providing accurate study feasibility forecasting for global biotechnology sponsors.
"As an industry experiencing unprecedented volatility, there is a great need to quantify uncertainty while identifying reliable paths to study enrollment success," said Rohit Nambisan, Lokavant CEO and Founder. "Spectrum analyzes country approval timelines, site activations, indication, and enrollment rates, leveraging the most advanced models to quantify levels of uncertainty with each forecast and each new variable. Like weather forecasting, predicting enrollment empowers teams to make better decisions."
Learn more about Spectrum v15 at DIA 2025 – request a meeting at [e-mail].
About Lokavant
Lokavant is the trailblazer in AI for Study Forecasting, transforming how clinical trials are planned and executed by delivering clarity in an uncertain industry. Its flagship solution, Spectrum, enables clinical teams to independently forecast enrollment timelines and assess operational risks – both before and during study execution. Powered by historical data from over 500,000 trials and advanced AI models, including generative AI, machine learning, and causal AI, Lokavant delivers real-time forecasts with over 80% confidence in minutes. Sponsors and CROs use Spectrum to reduce non-conformance events by 70%, improve forecasting accuracy by 70x, and cut study timelines and costs. Learn more at www.lokavant.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250423322272/en/
Contacts
Media Contact: Lisa Barbadora, Big Valley for Lokavant+1 (610) [e-mail] / [e-mail]